While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are two cash-producing companies that reinvest wisely to drive long-term success and one that may struggle to keep up.
One Stock to Sell:
Somnigroup (SGI)
Trailing 12-Month Free Cash Flow Margin: 10.1%
Established through the merger of Tempur-Pedic and Sealy in 2012, Somnigroup (NYSE: SGI) is a bedding manufacturer known for its innovative memory foam mattresses and sleep products
Why Do We Steer Clear of SGI?
- 11.6% annual revenue growth over the last five years was slower than its consumer discretionary peers
- Free cash flow margin is anticipated to expand by 1.5 percentage points over the next year, providing additional flexibility for investments and share buybacks/dividends
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
At $62.60 per share, Somnigroup trades at 17.7x forward P/E. Dive into our free research report to see why there are better opportunities than SGI.
Two Stocks to Watch:
Dycom (DY)
Trailing 12-Month Free Cash Flow Margin: 6.9%
Working alongside some of the most popular mobile carriers in the world, Dycom (NYSE: DY) builds and maintains telecommunications infrastructure.
Why Will DY Outperform?
- Market share has increased this cycle as its 24.6% annual revenue growth over the last two years was exceptional
- Performance over the past two years shows its incremental sales were extremely profitable, as its annual earnings per share growth of 37% outpaced its revenue gains
- Free cash flow margin expanded by 6.4 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
Dycom’s stock price of $273.47 implies a valuation ratio of 15.2x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
Encompass Health (EHC)
Trailing 12-Month Free Cash Flow Margin: 12.6%
With a network of 161 specialized facilities across 37 states and Puerto Rico, Encompass Health (NYSE: EHC) operates inpatient rehabilitation hospitals that help patients recover from strokes, hip fractures, and other debilitating conditions.
Why Are We Fans of EHC?
- Free cash flow margin increased by 3.4 percentage points over the last five years, giving the company more capital to invest or return to shareholders
- Industry-leading 15.8% return on capital demonstrates management’s skill in finding high-return investments, and its returns are climbing as it finds even more attractive growth opportunities
- Returns on capital are growing as management capitalizes on its market opportunities
Encompass Health is trading at $123.16 per share, or 19.2x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
